A detailed history of Virtus ETF Advisers LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 27,678 shares of ABCL stock, worth $73,346. This represents 0.03% of its overall portfolio holdings.

Number of Shares
27,678
Previous 27,185 1.81%
Holding current value
$73,346
Previous $80,000 11.25%
% of portfolio
0.03%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.39 - $3.49 $1,178 - $1,720
493 Added 1.81%
27,678 $71,000
Q2 2024

Aug 14, 2024

BUY
$2.73 - $4.73 $31,048 - $53,794
11,373 Added 71.93%
27,185 $80,000
Q1 2024

May 15, 2024

SELL
$4.29 - $5.97 $4,641 - $6,459
-1,082 Reduced 6.4%
15,812 $71,000
Q4 2023

Feb 15, 2024

BUY
$3.91 - $5.93 $13,720 - $20,808
3,509 Added 26.22%
16,894 $96,000
Q3 2023

Nov 07, 2023

SELL
$4.6 - $7.95 $6,113 - $10,565
-1,329 Reduced 9.03%
13,385 $61,000
Q2 2023

Aug 14, 2023

BUY
$5.66 - $7.59 $26,777 - $35,908
4,731 Added 47.39%
14,714 $95,000
Q1 2023

May 15, 2023

SELL
$7.31 - $11.18 $28,099 - $42,975
-3,844 Reduced 27.8%
9,983 $75,000
Q4 2022

Feb 14, 2023

BUY
$9.48 - $14.52 $18,495 - $28,328
1,951 Added 16.43%
13,827 $140,000
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $846 - $1,258
92 Added 0.78%
11,876 $117,000
Q1 2022

May 16, 2022

SELL
$7.46 - $14.14 $5,207 - $9,869
-698 Reduced 5.59%
11,784 $115,000
Q4 2021

Feb 14, 2022

BUY
$12.99 - $17.73 $49,595 - $67,693
3,818 Added 44.07%
12,482 $178,000
Q3 2021

Nov 15, 2021

SELL
$14.85 - $21.34 $6,637 - $9,538
-447 Reduced 4.91%
8,664 $174,000
Q2 2021

Aug 10, 2021

BUY
$20.19 - $34.17 $183,951 - $311,322
9,111 New
9,111 $200,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $756M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.